

From: [REDACTED]
Sent: 15 January 2011 20:41
To: [REDACTED]
Subject: RE: Appeal: Initial scrutiny letter - Renal cell carcinoma (advanced and/or metastatic; 2nd line) - everolimus

Follow Up Flag: Follow up
Flag Status: Flagged

Dear [REDACTED],

I confirm that KCUK has no further written submission to make in this regard.

So sorry to have occasioned you to have to write a reminder email to me. But I hadn't gathered that I needed to confirm this.

Many thanks.

Best Wishes,

[REDACTED]

From: [REDACTED]
Sent: Friday, January 14, 2011 4:08 PM
To: [REDACTED]
Cc: [REDACTED]; [REDACTED]; [REDACTED]
Subject: RE: Appeal: Initial scrutiny letter - Renal cell carcinoma (advanced and/or metastatic; 2nd line) - everolimus

Dear [REDACTED]

Further to my email sent on 17 December, I am writing to remind you that the deadline for response to the initial scrutiny letter is 5pm on Monday 17 January.

If there is no further information that Kidney Cancer UK would like to provide for their appeal point, then please can this be confirmed by email by the deadline stated above.

Kind regards

[REDACTED]

Project Manager - Corporate Office
National Institute for Health and Clinical Excellence MidCity Place | 71 High
Holborn | London WC1V 6NA | United Kingdom
Tel: | Fax:
Web: <http://nice.org.uk>

From: [REDACTED]
Sent: 17 December 2010 12:45
To: [REDACTED]
Cc: [REDACTED]; [REDACTED]
Subject: Appeal: Initial scrutiny letter - Renal cell carcinoma (advanced and/or metastatic; 2nd line) - everolimus

Importance: High

Dear [REDACTED]

In response to the Kidney Cancer UK appeal against the above technology appraisal, please find attached the initial scrutiny letter from the Appeal Committee Chair.

If Kidney Cancer UK would like to respond please can you send this to me by no later than Monday 17 January.

Kind regards

[REDACTED]

Project Manager - Corporate Office

National Institute for Health and Clinical Excellence MidCity Place | 71 High

Holborn | London WC1V 6NA | United Kingdom

Tel: | Fax:

Web: <http://nice.org.uk>

The information contained in this message and any attachments is intended for the addressee(s) only. If you are not the addressee, you may not disclose, reproduce or distribute this message. If you have received this message in error, please advise the sender and delete it from your system. Any personal data sent in reply to this message will be used in accordance with provisions of the Data Protection Act 1998 and only for the purposes of the Institute's work.

All messages sent by NICE are checked for viruses, but we recommend that you carry out your own checks on any attachment to this message. We cannot accept liability for any loss or damage caused by software viruses.

<http://www.nice.org.uk>

Delivered via MessageLabs
